



St. Jude Medical Company Overview

St. Jude Medical develops medical technology and services that focus on putting more control into the hands of those who treat cardiac, neurological and chronic pain patients worldwide. The company is dedicated to advancing the practice of medicine by reducing risk wherever possible and contributing to successful outcomes for every patient. Headquartered in St. Paul, Minn., St. Jude Medical employs more than 14,000 people worldwide and has four major focus areas that include: cardiac rhythm management, atrial fibrillation, cardiovascular and neuromodulation.

The St. Jude Medical product portfolio includes implantable cardioverter defibrillators (ICDs), cardiac resynchronization therapy (CRT) devices, pacemakers, electrophysiology catheters, mapping and visualization systems, vascular closure devices, heart valve replacement and repair products, spinal cord stimulation and deep brain stimulation devices.

COMPANY FACTS

Global Headquarters	St. Paul, Minnesota, USA
Website	www.sjm.com
Stock Exchange	New York Stock Exchange (NYSE) under "STJ" symbol
Founded	1976 in St. Paul, Minnesota, USA
2009 Net Sales	\$4.681 billion
Global Reach	St. Jude Medical has operations and manufacturing facilities worldwide, with products sold in more than 100 countries.
Employees	More than 14,000 employees worldwide

HIGHLIGHTS

- St. Jude Medical has significant programs in place that we expect to benefit our 2011 and 2012 margins and capture EPS (earnings per share) leverage while maintaining our investments in long-term growth drivers.
- We plan to continue to invest at least 12% of sales in R&D with a strong focus on continued investment in clinical trials for the benefit of our customers and the patients they serve.
- Five-year compounded annual growth rate was 15.5% from 2004 through 2009.

St. Jude Medical, Inc.
Global Headquarters
One St. Jude Medical Drive
St. Paul, MN 55117 USA

Investor and Media Contact

Angie Craig
Tel: +1 651.756.2191

Additional Investor Contact

J.C. Weigelt
Tel: +1 651.756.4347

Additional Media Contacts

International
Marisa Bluestone
Tel: +1 651.756.6739

Cardiac Rhythm Management

Atrial Fibrillation
Amy Jo Meyer
Tel: +1 651.756.3029

Cardiovascular
Kate Stoltenberg
Tel: +1 651.756.6293

Neuromodulation
Denise Landry
Tel: +1 972.309.8085

GROWTH AT ST. JUDE MEDICAL

St. Jude Medical is committed to continuous innovation and growth in its people, product portfolios and clinical research programs. The company sees growth opportunities in each of its technology platforms:

Atrial Fibrillation: St. Jude Medical is a pioneer and leader in the AF market, which is estimated to be about \$2 billion. The company offers the industry's broadest product portfolio for the EP lab, aiding physicians in the diagnosis and treatment of cardiac arrhythmias. Our sponsorship of IRASE AF, which could lead to an AF indication for an ablation catheter, and CABANA are reflective of the company's commitment to advancing the management of AF through important clinical research.

Cardiac Rhythm Management: The worldwide CRM market was approximately \$11 billion in 2009. The St. Jude Medical CRM business launched several new devices in 2009 including RF pacemakers, an ST segment monitoring ICD, and a cellular adaptor for the Merlin@Home™ remote monitoring system. The company will begin clinical trials on a number of new technologies in 2010, including a left atrial pressure monitor, an MRI-compatible pacemaker and a quadripolar pacing system.

Neuromodulation: St. Jude Medical participates in the \$1 billion spinal cord stimulator market and the \$360 million deep brain stimulation (DBS) market. The company launched its first DBS system in Europe during 2009, and has the smallest, longest lasting spinal cord stimulator on the market. The company also has clinical research programs focused on potential indications for depression, Parkinson's disease and numerous other disease states.

Cardiovascular: St. Jude Medical participates in segments of the interventional cardiology and cardiac surgery markets totaling approximately \$2.5 billion. We have strong franchises in FFR (Fractional Flow Reserve) measurement systems, vascular closure and heart valve repair, and with the launch of Trifecta™ and Roll-x™ we will enter the markets for pericardial stented tissue valves and coronary guide wires during the second half of 2010.

St. Jude Medical, Inc.
Global Headquarters
One St. Jude Medical Drive
St. Paul, MN 55117 USA

Investor and Media Contact

Angie Craig
Tel: +1 651.756.2191

Additional Investor Contact

J.C. Weigelt
Tel: +1 651.756.4347

Additional Media Contacts

International
Marisa Bluestone
Tel: +1 651.756.6739

Cardiac Rhythm Management

Atrial Fibrillation
Amy Jo Meyer
Tel: +1 651.756.3029

Cardiovascular

Kate Stoltenberg
Tel: +1 651.756.6293

Neuromodulation

Denise Landry
Tel: +1 972.309.8085

PERFORMANCE AND PROGRESS

Revenue (in millions)




Research & Development (in millions)




Reported Earnings Per Share



2009 Product Revenue Mix



2009 Sales By Geography



ST. JUDE MEDICAL™
MORE CONTROL. LESS RISK.